DK0865294T3 - Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater - Google Patents

Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater

Info

Publication number
DK0865294T3
DK0865294T3 DK96926873T DK96926873T DK0865294T3 DK 0865294 T3 DK0865294 T3 DK 0865294T3 DK 96926873 T DK96926873 T DK 96926873T DK 96926873 T DK96926873 T DK 96926873T DK 0865294 T3 DK0865294 T3 DK 0865294T3
Authority
DK
Denmark
Prior art keywords
methods
reducing
reduced levels
protein preparations
blood lipids
Prior art date
Application number
DK96926873T
Other languages
English (en)
Inventor
Mary Ann Pelleymounter
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK0865294T3 publication Critical patent/DK0865294T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK96926873T 1995-08-17 1996-08-02 Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater DK0865294T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51626395A 1995-08-17 1995-08-17
PCT/US1996/012674 WO1997006816A1 (en) 1995-08-17 1996-08-02 Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions

Publications (1)

Publication Number Publication Date
DK0865294T3 true DK0865294T3 (da) 2004-06-28

Family

ID=24054813

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96926873T DK0865294T3 (da) 1995-08-17 1996-08-02 Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater

Country Status (13)

Country Link
US (1) US20020147142A1 (da)
EP (1) EP0865294B1 (da)
JP (1) JP4173913B2 (da)
AT (1) ATE259650T1 (da)
AU (1) AU6688896A (da)
CA (1) CA2229450A1 (da)
DE (1) DE69631605T2 (da)
DK (1) DK0865294T3 (da)
ES (1) ES2216055T3 (da)
MX (1) MX9801159A (da)
PT (1) PT865294E (da)
WO (1) WO1997006816A1 (da)
ZA (1) ZA966798B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
JPH11508134A (ja) * 1995-06-22 1999-07-21 イーライ・リリー・アンド・カンパニー 肥満症蛋白質中間体およびその製法と使用
US5830450A (en) * 1996-06-19 1998-11-03 Lallone; Roger L. Compositions of leptin bound to an apolipoprotein
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6808921B1 (en) 1998-03-27 2004-10-26 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6436707B1 (en) 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
ATE280588T1 (de) * 1998-08-10 2004-11-15 Amgen Inc Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
DK1444516T3 (da) 2001-10-22 2010-11-15 Amgen Inc Anvendelse af leptin til behandling af lipoatrofi hos mennesker og fremgangsmåde til at bestemme en prædisposition for denne behandling
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
GB0307367D0 (en) * 2003-03-29 2003-05-07 Twg Composition and method for treating the gastro-intestinal tract
EP1462116A1 (en) * 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
AU2004313245B2 (en) 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2286837A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and obesity related diseases
US7629315B2 (en) * 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
BR122021020041B1 (pt) 2010-09-28 2023-03-07 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
EP3434268B1 (en) 2012-09-27 2022-04-20 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
PT3509624T (pt) 2016-09-12 2023-08-28 Amryt Pharmaceuticals Inc Métodos de deteção de anticorpos neutralizantes anti-leptina

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
PT865294E (pt) 2004-07-30
WO1997006816A1 (en) 1997-02-27
JP4173913B2 (ja) 2008-10-29
MX9801159A (es) 1998-05-31
EP0865294A1 (en) 1998-09-23
EP0865294B1 (en) 2004-02-18
DE69631605D1 (de) 2004-03-25
US20020147142A1 (en) 2002-10-10
DE69631605T2 (de) 2005-01-05
AU6688896A (en) 1997-03-12
ES2216055T3 (es) 2004-10-16
ZA966798B (en) 1997-02-19
ATE259650T1 (de) 2004-03-15
JPH11511165A (ja) 1999-09-28
CA2229450A1 (en) 1997-02-27

Similar Documents

Publication Publication Date Title
DK0865294T3 (da) Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69625691T2 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
NO951761L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
DK0833649T4 (da) Proteinhydrolysatpræparater til forebyggelse eller behandling af allergier
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
DE69827192D1 (de) Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
DE69703689T2 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
NO983999L (no) Peptidimmunogener for vaksinasjon mot og behandling av allergi
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
DE69822496D1 (de) Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen
HUP9900506A2 (hu) Protrombinszármazékok
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer
DK0740547T3 (da) Liposomer indeholdende deri indkapslede proteiner, fremgangsmåde til deres fremstilling, samt farmaceutiske og kosmetiske p
ATE238796T1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
EP0680763A3 (en) Stable preparation for the treatment of blood coagulation disorders comprising an activated coagulation factor and lipid vesicles
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
NO995459D0 (no) Vevsfaktor for påvirkning av blodkardannelse
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein
NO874320D0 (no) Fremgangsmaate for bestemmelse av funksjonelle nivaaer av protein c i humant plasma.
UA31401A (uk) Спосіб хірургічного лікування портальної гіпертензії
UA10743A (uk) Спосіб лікуваhhя хроhічhої лімфовеhозhої hедостатhості hижhіх кіhцівок